Alan X. Ji
BridgeBio (United States)(US)Bridge Pharma (United States)(US)
Publications by Year
Research Areas
Amyloidosis: Diagnosis, Treatment, Outcomes, Parathyroid Disorders and Treatments, Ubiquitin and proteasome pathways, Glycosylation and Glycoproteins Research, Coagulation, Bradykinin, Polyphosphates, and Angioedema
Most-Cited Works
- → The integrated landscape of driver genomic alterations in glioblastoma(2013)554 cited
- → Crystal Structure of KLHL3 in Complex with Cullin3(2013)78 cited
- → Structural Insights into KCTD Protein Assembly and Cullin3 Recognition(2015)74 cited
- → Structure and dynamics of a pentameric KCTD5/CUL3/Gβγ E3 ubiquitin ligase complex(2024)14 cited
- → Acoramidis produces near-complete TTR stabilization in blood samples from patients with variant transthyretin amyloidosis that is greater than that achieved with tafamidis(2023)7 cited
- → Structure and dynamics of a pentameric KCTD5/Cullin3/Gβγ E3 ubiquitin ligase complex(2023)5 cited
- → Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up(2025)5 cited
- → Circulating transthyretin and retinol binding protein 4 levels among middle-age V122I TTR carriers in the general population(2024)5 cited
- → MO040: Development of BBP-711, a small molecule inhibitor of glycolate oxidase for primary hyperoxaluria type 1 and recurrent kidney stone formers(2022)4 cited
- → Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study(2024)3 cited